伊佳 徐德铎 侯幸赟 王志鹏 陶霞

    摘 要 目的：综合评价硼替佐米用于多发性骨髓瘤治疗的临床安全性、有效性、经济性、创新性、适宜性和可及性。方法：通过各级来源证据对指标进行整合分析。结果：纳入6篇meta分析和5篇药物经济学研究文章，采用硼替佐米方案治疗多发性骨髓瘤的总缓解率优于对照组，不良反应发生率为64.06%，血小板减少和外周神经病变发生率较高。硼替佐米存储要求低、产能充足、部分厂家产品居民可负担性较好，但创新数据不足。结论：硼替佐米安全性、有效性明确，适宜性、可及性较好，部分方案成本效益较好。

    关键词 硼替佐米 临床综合评价 多发性骨髓瘤

    中图分类号：R979.19； R733.3 文献标志码：A 文章编号：1006-1533(2024)01-0033-06

    引用本文 伊佳， 徐德铎， 侯幸赟， 等. 硼替佐米治疗多发性骨髓瘤的临床综合评价[J]. 上海医药， 2024， 45(1)： 33-38.

    Clinical comprehensive evaluation of bortezomib in the treatment of multiple myeloma

    YI Jia， XU Deduo， HOU Xingyun， WANG Zhipeng， TAO Xia

    (Department of Pharmacy， Shanghai Changzheng Hospital affiliated to Naval Military Medical University， Shanghai 200003， China)

    ABSTRACT Objective： To comprehensively evaluate the clinical safety， efficacy， economy， innovation， suitability and accessibility of bortezomib for the treatment of multiple myeloma. Methods： The indicators were analyzed in an integrated manner through evidence from all levels of sources. Results： Six systematic reviews/mata-analysis and 5 pharmacoeconomic studies were enrolled. The overall response rate in multiple myeloma patients treated with bortezomib were better than without ......